A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Cancer Cell · 2024-02 · 42 (2) · 198-208.e3
DOI: 10.1016/j.ccell.2023.12.004 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Cell, 2024-02. Verfasst von Caicun Zhou und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: caicunzhoudr@163.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: caicunzhoudr@163.com.
- Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430000, China.
- LTD Israeli-Georgian Medical Research Clinic "Helsicore", Tbilisi 0112, Georgia.
- Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.
- Department of Pneumology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
- Department of Pneumology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Zitieren
APA
Zhou, C., Hu, Y., Arkania, E., Kilickap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., Sun, H., Luo, F., Shi, J., Zang, A., Pan, Y., Chen, Z., Jia, Z., Kuchava, V., Lu, P., …, & ASTRUM-004 Investigators (2024). A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell, 42(2), 198-208.e3. https://doi.org/10.1016/j.ccell.2023.12.004
Vancouver
Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024;42(2):198-208.e3. doi:10.1016/j.ccell.2023.12.004
BibTeX
@article{Zhou2024,
author = {Zhou, Caicun and Hu, Yanping and Arkania, Ekaterine and Kilickap, Saadettin and Ying, Kejing and Xu, Fei and Wu, Lin and Wang, Xiang and Viguro, Maksym and Makharadze, Tamta and Sun, Hongmei and Luo, Feng and Shi, Jianhua and Zang, Aimin and Pan, Yueyin and Chen, Zhendong and Jia, Zhongyao and Kuchava, Vladimer and Lu, Ping and Zhang, Ling and Cheng, Ying and Kang, Wenying and Wang, Qingyu and Yu, Haoyu and Li, Jing and Zhu, Jun and ASTRUM-004 Investigators, ASTRUM-004 Investigators},
title = {A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {2},
pages = {198--208.e3},
doi = {10.1016/j.ccell.2023.12.004}
}
EUVIMED